---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040327"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:48:47.565152+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q3 net loss $4.2M ($0.41/sh) vs $5.7M loss year ago; cash $29.7M

## Summary
- Net loss for Q3 2023 was $4.2M ($0.41 per share) compared with net loss of $5.7M ($0.70 per share) in Q3 2022.
- R&D expenses increased to $4.2M from $3.9M, driven by clinical advancement of CC-42344 and CDI-988 trials.
- Cash and equivalents $29.7M as of Sep 30, 2023, down from $37.1M at Dec 31, 2022; working capital $30.3M.
- Enrollment underway in Phase 1 trial for dual coronavirus-norovirus oral protease inhibitor CDI-988.
- Phase 2a human challenge trial for oral influenza A drug CC-42344 expected to begin dosing before year-end 2023; inhaled CC-42344 Phase 1 planned H1 2024.

## SEC filing metadata
- accession: 0001493152-23-040327
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/0001493152-23-040327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040327
- JSON: https://secwatch.observer/filing/0001493152-23-040327.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040327.txt

## Key facts
- Earnings Releases
  Cocrystal Pharma, Inc. reported financial results for three and nine months ended September 30, 2023.
  - Period: three and nine months ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Cocrystal Pharma, Inc. (the "Company") issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/0001493152-23-040327-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.